Strong H2 2023 drives record sales for Wiltshire’s Alliance Pharma

Chippenham-based Alliance Pharma has posted revenues of £187 million for the year ended 31 December 2023 – up 8 per cent on 2022 – with a strong second half performance driving record sales.

The consumer healthcare group says it’s now ‘well positioned for growth over the medium term’ as its flagship Kelo-Cote scar treatment product continues to see strong consumer demand.

Meanwhile, Alliance’s latest US acquisition, ScarAway, has exceeded expectations, generating revenues of £9.9 million – up 20 per cent.

These latest results follow the appointments of Camillo Pane as chair of Alliance in February, followed by new CEO Nick Sedgwick last month.

Commenting on the results, Andrew Franklin, chief financial officer, said: “Our portfolio continues to provide a solid platform from which to grow our consumer healthcare brands and generate strong cash flow.

“In 2023, we increased marketing investment, launching award winning advertising campaigns for Kelo-Cote and MacuShield to accelerate organic sales growth while bringing new products to market.

“Our revenues through ecommerce are building strongly as we strengthen our network of specialist partners and internal capabilities and enter new geographies.

“We remain confident in our medium to long-term performance as we focus our resources on those market segments in which we already have a strong presence and expertise in order to drive solid organic revenue growth above that of the broader consumer healthcare market.”